Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 17/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 17/20 | 1.00 |
| ▸ | RELA | Q04206 | 17/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CLPX | O76031 | 1/20 | 0.81 |
| ▸ | VCP | P55072 | 1/20 | 0.81 |
| ▸ | RORA | P35398 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Withaferin A SCHEMBL12309163 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL29398581 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL30782710 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL12309137 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL20136632 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL24075907 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL11950371 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL157208 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL18372363 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| SCHEMBL12309145 | 0.94 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158152-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIMINUTION OF BONE TISSUE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-09 | — | — | US | disclosed |
| US-20160158152-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIMINUTION OF BONE TISSUE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158152-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIMINUTION OF BONE TISSUE | WNT3A, DKK1, WNT3 | NFKB1 1864/4885NFKB2 714/4885RELA 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.